Published in BMC Cancer on October 05, 2013
Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer. Breast Cancer Res (2015) 0.91
Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies. BMC Cancer (2015) 0.88
DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer. Clin Epigenetics (2015) 0.87
Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. Breast Cancer Res (2014) 0.82
Tissue specific DNA methylation in normal human breast epithelium and in breast cancer. PLoS One (2014) 0.82
FOXA1 positively regulates gene expression by changing gene methylation status in human breast cancer MCF-7 cells. Int J Clin Exp Pathol (2015) 0.81
Transcriptome-wide signatures of tumor stage in kidney renal clear cell carcinoma: connecting copy number variation, methylation and transcription factor activity. Genome Med (2014) 0.81
Epigenetics in breast and prostate cancer. Methods Mol Biol (2015) 0.79
An improved sequencing-based strategy to estimate locus-specific DNA methylation. BMC Cancer (2015) 0.78
ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter. Epigenetics (2014) 0.77
Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. Oncotarget (2016) 0.76
DNA methylation of heparanase promoter influences its expression and associated with the progression of human breast cancer. PLoS One (2014) 0.76
Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. BMC Cancer (2017) 0.75
DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study. Epigenetics (2016) 0.75
The association of PTEN hypermethylation and breast cancer: a meta-analysis. Onco Targets Ther (2016) 0.75
Heterogeneous DNA Methylation Patterns in the GSTP1 Promoter Lead to Discordant Results between Assay Technologies and Impede Its Implementation as Epigenetic Biomarkers in Breast Cancer. Genes (Basel) (2015) 0.75
The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review. Sci Rep (2016) 0.75
Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma. Epigenetics (2016) 0.75
Association between MGMT Promoter Methylation and Risk of Breast and Gynecologic Cancers: A Systematic Review and Meta-Analysis. Sci Rep (2017) 0.75
Mechanisms of Breast Cancer in Shift Workers: DNA Methylation in Five Core Circadian Genes in Nurses Working Night Shifts. J Cancer (2017) 0.75
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
The epigenomics of cancer. Cell (2007) 30.91
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
A gene hypermethylation profile of human cancer. Cancer Res (2001) 8.93
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer (2003) 2.18
Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci U S A (1996) 1.99
Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res (2010) 1.97
Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res (1998) 1.91
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res (2003) 1.89
Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer (2004) 1.82
MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther (2004) 1.82
Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res (1998) 1.81
Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol (2006) 1.69
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
The epigenetics of breast cancer. Mol Oncol (2010) 1.57
Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res (2002) 1.57
Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry. Nucleic Acids Res (2003) 1.46
Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res (2003) 1.45
DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res (2010) 1.44
Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol (2010) 1.44
Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol (2004) 1.39
PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer (2004) 1.33
Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res (2008) 1.20
Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res (2010) 1.18
Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics (2012) 1.07
Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer Biol Ther (2004) 1.06
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer (2010) 1.05
GSTP1 promoter hypermethylation is an early event in breast carcinogenesis. Virchows Arch (2007) 1.05
Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat (2006) 1.01
Prognostic significance of RASSF1A promoter methylation in operable breast cancer. Clin Biochem (2009) 0.98
Methylation of the p16(Ink4a) tumor suppressor gene 5'-CpG island in breast cancer. Cancer Lett (2001) 0.97
Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol (2003) 0.96
High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer. Pathology (2005) 0.93
Methylation of E-cadherin and hMLH1 genes in Indian sporadic breast carcinomas. Indian J Exp Biol (2006) 0.79
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Signatures of mutational processes in human cancer. Nature (2013) 21.63
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
International network of cancer genome projects. Nature (2010) 20.35
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet (2011) 5.62
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39
DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLoS Biol (2004) 4.96
Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res (2009) 4.58
Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res (2006) 4.25
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet (2011) 3.95
Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92
Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell (2004) 3.73
Complete pipeline for Infinium(®) Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation. Epigenomics (2012) 3.50
Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res (2007) 3.01
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol (2002) 2.87
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics (2006) 2.86
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
De novo quantitative bisulfite sequencing using the pyrosequencing technology. Anal Biochem (2004) 2.73
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One (2011) 2.70
CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics (2004) 2.65
Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. BMC Genomics (2002) 2.42
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat (2011) 2.23
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal (2010) 2.16
Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res (2010) 2.09
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol (2007) 2.06
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res (2004) 2.03
Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res (2010) 2.01
Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res (2004) 2.01
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res (2005) 2.00
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res (2003) 1.89
Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res (2009) 1.84
Discovery and validation of breast cancer subtypes. BMC Genomics (2006) 1.83
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A (2011) 1.78
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics (2012) 1.74
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol (2010) 1.71
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis (2006) 1.70
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol (2009) 1.68
Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res (2010) 1.64
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther (2006) 1.64
Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol (2010) 1.63
PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat (2005) 1.61
Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.59
Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Canc Netw (2005) 1.59
Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet (2009) 1.58
EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J Thorac Oncol (2011) 1.58
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
The epigenetics of breast cancer. Mol Oncol (2010) 1.57
Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. Genes Chromosomes Cancer (2008) 1.54
Specific epigenetic alterations of IGF2-H19 locus in spermatozoa from infertile men. Eur J Hum Genet (2010) 1.48
Improved lymph node harvest from resected colon cancer specimens did not cause upstaging from TNM stage II to III. World J Surg (2011) 1.47
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer (2010) 1.46
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol (2010) 1.45
Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol (2010) 1.44
Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene (2004) 1.42
Sex- and diet-specific changes of imprinted gene expression and DNA methylation in mouse placenta under a high-fat diet. PLoS One (2010) 1.41
Merging transcriptomics and metabolomics--advances in breast cancer profiling. BMC Cancer (2010) 1.41
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat (2010) 1.40
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell (2011) 1.40
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat (2003) 1.33
Genomics in breast cancer-therapeutic implications. Nat Clin Pract Oncol (2005) 1.32
Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes. Breast Cancer Res (2007) 1.30
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol (2012) 1.29
Deciphering normal blood gene expression variation--The NOWAC postgenome study. PLoS Genet (2010) 1.29
11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat (2012) 1.26
Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol (2010) 1.26